Expertise in
12
conditions

Thomas Foltynie

UCL Queen Square Institute Of Neurology, 
London, ENG, GB 
Expertise in
12
conditions
UCL Queen Square Institute Of Neurology, 
London, ENG, GB 

Overview

Thomas Foltynie practices practicing medicine in London, United Kingdom.

Mr. Foltynie is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Drug Induced Dyskinesia, Deep Brain Stimulation, and Thalamotomy.

He is actively involved in clinical research, co-authoring 207 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

UCL Queen Square Institute Of Neurology, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)
A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)
Enrollment Status: Completed
Publish Date: November 08, 2021
Intervention Type: Drug
Study Drug: Ursonorm
Study Phase: Phase 2
A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease
A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease
Enrollment Status: Completed
Publish Date: April 15, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

207 Total Publications

Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital data.
Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital data.
Journal: BMJ neurology open
Published: May 22, 2026

Frequently Asked Questions about Thomas Foltynie

Is Thomas Foltynie a top-rated expert for Parkinson's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Thomas Foltynie is classified as an Elite expert for Parkinson's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Thomas Foltynie participate in research or clinical trials?

Yes. Thomas Foltynie has published 207 articles and abstracts on conditions like Parkinson's Disease. You can view a list of Thomas Foltynie's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Foltynie's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile